A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J Harrison, Hang Quach, Emma Link, John F Seymour, David S Ritchie, Sam Ruell, Joanne Dean, Henry Januszewicz, Ricky Johnstone, Paul Neeson, Michael Dickinson, Jean Nichols, H Miles Prince
Blood | AMER SOC HEMATOLOGY | Published : 2011
This was an investigator-initiated trial with financial support from Celgene (formerly Gloucester Pharmaceuticals). S.J.H. receives research support from the Vaccari Foundation. R.J. receives research support from the National Health and Medical Research Council of Australia, the Victorian Cancer Agency, and the Leukemia Foundation of Australia.J.N. is an employee of Celgene Corporation. S.J.H. and H. M. P. receive research funding from and have been members of advisory boards for Celgene Corporation and Janssen Cilag. J.F.S. and D. S. R. receive research funding from and have been members of advisory boards for Celgene Corporation. P.N. and H. Q. receive research funding from Celgene Corporation.